CRSP vs VRTX
CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | CRSP | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $47.24 | $472.57 | |
| Market cap as of 2026-07-23 | $4.6B | $121.4B | |
| P/E as of 2026-07-23 | n/a | 27.98 | |
| PEG as of 2026-07-23 | -0.21 | 2.31 | CRSP lower |
| Net margin as of 2026-07-23 | -13856.5% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-23 | n/a | +86.2% | |
| Operating margin as of 2026-07-23 | -15754.2% | +38.3% | VRTX higher |
| ROE as of 2026-07-23 | -30.9% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | -24.5% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-23 | 0.32 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-23 | -89.1% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | +43.1% | +10.4% | CRSP higher |
| Beta as of 2026-07-23 | 1.77 | 0.30 | |
| 1-year return as of 2026-07-22 close | -26.3% | +0.5% | VRTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.